Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
C Rolfo, E Giovannetti, DS Hong, T Bivona… - Cancer treatment …, 2014 - Elsevier
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
G Bronte, C Rolfo, E Giovannetti, G Cicero… - Critical reviews in …, 2014 - Elsevier
Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …
Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
DB Costa, KSH Nguyen, BC Cho, LV Sequist… - Clinical cancer …, 2008 - AACR
Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …
[HTML][HTML] Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib
T Katayama, J Shimizu, K Suda, R Onozato… - Journal of Thoracic …, 2009 - Elsevier
Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung …
YJ Lee, HJ Choi, SK Kim, J Chang… - … Journal of the …, 2010 - Wiley Online Library
BACKGROUND: We investigated the risk of central nervous system (CNS) failure after
clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) …
clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) …
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study
Most patients with non-small-cell lung cancer (NSCLC) who initially respond to epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …
Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
Y Tomizawa, Y Fujita, A Tamura, M Shirai, S Shibata… - Lung Cancer, 2010 - Elsevier
PURPOSE: We investigated the efficacy of gefitinib re-challenge for the patients who
responded to initial treatment with gefitinib and acquired resistance to gefitinib thereafter …
responded to initial treatment with gefitinib and acquired resistance to gefitinib thereafter …
[HTML][HTML] Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment
DH Lee, SW Kim, C Suh, DH Yoon, EJ Yi, JS Lee - Annals of oncology, 2008 - Elsevier
Background: Both gefitinib and erlotinib are reversible epidermal growth factor receptor
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …